Aeolus is developing a portfolio of novel metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL , is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. The Company is also developing AEOL as a treatment for Parkinson s disease and AEOL as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti viral therapies. For more information, please visit Aeolus s corporate website at www.aolsrx.com
Quote | Aeolus Pharms Inc (OTCMKTS:AOLS)
Last: | $1e-06 |
---|---|
Change Percent: | 0.0% |
Open: | $1e-06 |
Close: | $1e-06 |
High: | $1e-06 |
Low: | $1e-06 |
Volume: | 53,043 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Aeolus Pharms Inc (OTCMKTS:AOLS)
MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to ...
Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d...
Message Board Posts | Aeolus Pharms Inc (OTCMKTS:AOLS)
Subject | By | Source | When |
---|---|---|---|
Well it looks like David Cavalier has moved | Sheep | investorshub | 08/17/2021 6:35:07 PM |
Sweet volume flowing in. Sure hope we get | Sheep | investorshub | 06/11/2021 4:36:52 PM |
$AOLS will stop trading after Sept. 28th, 2021. | GetSeriousOK | investorshub | 05/24/2021 4:16:51 PM |
Wow someone is willing to buy. There is | Sheep | investorshub | 02/25/2021 6:47:16 PM |
And someone is still at it! | GetSeriousOK | investorshub | 02/21/2021 1:54:48 AM |
News, Short Squeeze, Breakout and More Instantly...
Aeolus Pharms Inc Company Name:
AOLS Stock Symbol:
OTCMKTS Market:
MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to ...